Optimer Pharmaceutical is another upcoming biotech with a chance for some momentum due to some upcoming game changing events. See my research below. Always do your own due diligence before buying any security and please see my diclaimer at the end of this report.
Notes on Fidaxomicin
- for treatment of Clostridium Difficile Infection or CDI
- Optimer recently received a priority review PDUFA date of May 30, 2011 for its NDA of Fidaxomicin and an advisory committee on April 5th:
http://www.optimerpharma.com/news.asp?news_story=145&page_num=&year=2011
Currently over 700k cases in U.S. per year ~ blockbuster potential
- Optimer plans to market the drug in the U.S. and use 3rd party outside the U.S.
- According to research by Decision Resources, Fidaximicin will be used by the majority of infectious disease specialists.
http://www.optimerpharma.com/news.asp?news_story=124&page_num=&year=2010
Additional product pipeline is as follows:

Another exciting product is Pruvel for the treatment of infectious diarrhea, however the company has voluntarily terminated its research study on this due to higher than expected incidences of mild skin rashes during use. There is no current timeline given by the Company as to how long it will take to research this skin rash issue.
Financial info:
On 2/16, Optimer completed a public offering of 6.9M shares at $11.25 per share, resulting in gross proceeds to Optimer of $77.6M ~ now that this offering is done, we can expect some momentum going into the panel and PDUFA event
Annual filing expecting on or around March 10, 2011
Last quarter filing
- Cash and cash equivalents $58M
- No long-term debt
- 9 mo revenue of only $1.3M
Stock data:
The stock price is currently at 11.90. The market just dropped considerably today possibly starting a small correction. My price range to buy would be around 11.25-11.50, adding more if it goes below 11. The year end earnings should not affect the stock too much as there are no revenues. My target is from $13-14, with further upside after approval of $15-16.
See my other reports on upcoming biotech momentum plays and sign up for e-mail alerts:
SPPI
https://pokerexpress.wordpress.com/2011/02/09/spectrum-pharmaceuticals-sppi-has-room-to-run/
XNPT
https://pokerexpress.wordpress.com/2011/02/03/xnpt-cleared-for-takeoff/
Disclosure: currently no position in OPTR
Disclaimer: I have never ever been paid or compensated by anyone for any stock I trade or discuss. None of the information posted on this site is to be construed as financial or investment advice. This information is not to be construed as an offer to buy or sell any security mentioned on this board. The creator of this board is not a licensed broker or financial advisor of any kind. The information on this site is gathered from sources available to the public. As consideration in using this board, all users agree, understand, and acknowledge the creator of the board is not liable or responsible for the accuracy or use of the information provided on this site and agree to indemnify and hold the creator of this board harmless from any liability resulting from the accuracy or inaccuracy of the information and from use of the information on this board. All of the information that I post on this board is public information available to anyone! You are responsible for your own trades and not the creator of this board. Please be aware that investing in securities carries the risk of losing some or all of your money.
Tags: biotech momentum, biotech run-up, biotech stock trading, biotech trading, free biotech stock tips, free stock trading ideas, momentum trading